GSK & Adolor Complete Enrolment Of Pivotal Entereg (alvimopan) Clinical Studies To Treat GI Side Effects Of Opioids Used For Persistent Pain

GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced today that GSK has completed enrolment of the Phase 3 clinical programme to evaluate the efficacy and safety of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal adverse